Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation
- None.
- None.
Insights
The collaboration between Evogene Ltd. and Verb Biotics LLC. is a strategic initiative in the burgeoning field of microbiome research, which has gained momentum due to its potential impact on human health. The partnership leverages Evogene's MicroBoost AI technology and Verb Biotics' knowledge in microbiome to enhance the development of probiotic strains capable of producing microbial metabolites. These metabolites are crucial for maintaining and improving human health and vitality.
From a biotechnological standpoint, the collaboration's primary innovation lies in targeting the enhancement of genetic pathways in microbes. This approach could lead to the discovery of novel metabolites, potentially resulting in new probiotic products with specific health benefits. The research and development efforts could also contribute to the diversification of Evogene's product portfolio, which is significant for the company's growth and market differentiation.
The probiotics market is witnessing rapid growth, projected to double by 2031. This expansion reflects a rising consumer demand for health products supported by scientific research. Thus, the output of this collaboration may position both companies favorably within this lucrative market. However, without financial terms disclosed, it is challenging to assess the direct financial impact on each company.
The strategic alliance between Evogene and Verb Biotics comes at a time when the global market for probiotics is experiencing significant growth, driven by increased consumer awareness and interest in health and wellness. The probiotics market is expected to reach approximately $114 billion by 2031, indicating a substantial market opportunity for both companies.
Evogene's AI-driven technology platform, MicroBoost AI, in combination with Verb Biotics' expertise, could lead to the development of superior probiotic strains. This partnership could provide a competitive edge in the market by accelerating the innovation cycle and potentially bringing new products to market more quickly. By focusing on the function-first approach mentioned by Noah Zimmerman, CTO of Verb Biotics, the collaboration may result in products that are not only effective but also align with consumer preferences for health solutions that are based on scientific evidence.
While the financial terms remain undisclosed, the long-term success of this collaboration will likely be evaluated based on the commercial viability of the probiotics developed and their acceptance in the market. The collaboration's success could also influence investor sentiment and stock performance for both companies, especially if it leads to breakthrough products that capture a significant share of the growing probiotics market.
Investors in the biotechnology sector often look for strategic partnerships like the one between Evogene and Verb Biotics as indicators of future growth potential. The collaboration's focus on developing new probiotic strains through advanced AI technology and microbiome expertise could lead to differentiated products in the high-growth probiotics market.
Without the financial terms of the agreement being public, it is difficult to quantify the immediate financial impact on Evogene's and Verb Biotics' balance sheets. However, the investment in R&D and potential future sales from successful probiotic strains could significantly influence both companies' revenues and profitability in the long term. The partnership may also attract additional investment in both companies, as it demonstrates a proactive approach to leveraging cutting-edge technology to address a growing market need.
It is important for stakeholders to monitor the development milestones and market reception of the resulting products to assess the partnership's effectiveness. The ability of both companies to capitalize on the expected market growth will depend on their success in innovating and commercializing the new probiotic strains.
The parties will identify and design probiotic bacteria that produce highly sustainable quantities of microbial metabolites, known to improve human health and vitality
The probiotics market is expected to double and reach approximately
The collaboration generates excellent synergy by combining Evogene's knowledge in bacterial-based product development utilizing its tech-engine MicroBoost AI with Verb Biotic's access to the genomes of various microbial strains that support the production of microbial metabolites vital for human health.
The financial terms of the agreement are not disclosed.
"Partnering with Evogene equips Verb Biotics with a powerful edge to revolutionize microbiome-driven health solutions. By leveraging Evogene's technology, we further streamline and de-risk our innovation pathway, prioritizing function-first approaches for optimal microbiome health", says Noah Zimmerman, CTO at Verb Biotics.
Eyal Ronan, EVP of Business Development at Evogene, noted, "This collaboration underscores Evogene's strategic commitment to leveraging our state-of-the-art AI tech-engines to new areas and opens doors for additional sectors in the life sciences industry to benefit from our powerful technology. Together with Verb Biotics, we aim to drive substantial progress in probiotics innovation and to stretch the boundaries of what can be achieved in this field."
About Verb Biotics:
Verb Biotics is a microbiome health ingredient company whose mission is to improve human health. Verb "biotics" ingredients are developed to deliver specific metabolites with targeted mechanisms of action to address functional health categories such as foundational gut microbiome health, gut-brain health, and healthy metabolism. From discovery to scale, the company applies science, biotechnology, and intentional development to deliver probiotics, postbiotics, and synbiotics for the business-to-business functional food, beverage, and dietary supplement industries.
To learn more, please visit us at www.verbbiotics.com and follow us on LinkedIn.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Verb Biotics, Evogene and its subsidiaries are using forward-looking statement in this press release when they discuss the development of new strains of probiotic bacteria, which produce a high sustainable quantity of microbial metabolites that improve human health and vitality, the expected growth of the probiotics market, and the expanding importance of the global microbiome research. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene's reports filed with the applicable securities authority. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections, and assumptions.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
Logo - https://mma.prnewswire.com/media/2335165/VerbBiotics.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-and-verb-biotics-enter-collaboration-agreement-to-advance-probiotic-innovation-302054575.html
SOURCE Evogene Ltd.; Verb Biotics LLC.
FAQ
What is the purpose of the collaboration agreement between Evogene Ltd. and Verb Biotics LLC.?
What is the expected growth of the probiotics market by 2031?
What technologies are being combined in the collaboration?
What does the collaboration underscore for Evogene?
